Loading news...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for GE HealthCare (GEHC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company's bold innovations first unveiled at the Radiological Society of North America's (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and.
Bank of New York Mellon Corp lowered its stake in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 1.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,194,405 shares of the company's stock after selling 62,766 shares during the period. Bank of
GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) is expected to release its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect GE HealthCare Technologies to post earnings of $1.43 per share and revenue of $5.6021 billion for the quarter. Individuals can find conference call details on the company's upcoming Q4
Anchor Capital Advisors LLC increased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 9.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 693,307 shares of the company's stock after purchasing an additional
/PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the
The rise of GEHC reflects its strong positioning in imaging, patient monitoring, and pharmaceutical diagnostics.
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
Investors aren't concerned enough about China competition or a generic rival, UBS says.
Medtronic, IQVIA and GE HealthCare show how medical device leaders are turning analytics, AI and enterprise data platforms into recurring revenue engines.
Pre-Market Stock Futures: Futures are trading mostly higher after another risk-off day on Wall Street on Wednesday. Despite more solid news on the inflation front, as the producer price index report came in below estimates, the swirling geopolitical issues around the world and at home are starting to weigh on Wall Street's bullishness. The potential... Here Are Thursday's Top Wall Street Analyst Research Calls: Applied Materials, BankUnited, Broadcom, Dell Technologies, DraftKings, Lam Research, NVIDIA, and More.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GE HealthCare Technologies Inc. (GEHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
D.A. Davidson and CO. increased its position in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 155.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,124 shares of the company's stock after buying an additional 8,585 shares during
Nvidia, AMD, Intel, and TSMC dominate CES 2026 with AI chips, open-source autonomy, and next-gen platforms as global demand accelerates across data centers and vehicles. Markets swing as Maduro's capture sparks drone stock rallies, AI regulation tightens, mega PAC funding surges, and tech earnings, chips, and defense dominate headlines.
Commonwealth Equity Services LLC reduced its stake in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 34.4% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 173,486 shares of the company's stock after selling 91,088 shares during the period. Commonwealth
Cerity Partners LLC grew its position in shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 20.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 373,570 shares of the company's stock after acquiring an additional 64,017 shares during the quarter. Cerity
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (“GE HealthCare”) announced today that it received notice on January 5, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares (or a greater amount as outlined in the offer documentation) of GE HealthCare common stock at a price of $54.20 per share in cash. Potemkin Limited's offer price of $54.20 per share is approximately 34.77 percent lower than the $83.09 closing per share pric.
Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Risk and Volatility Oramed Pharmaceuticals has a